Chang Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chang Huang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Cameron Allen
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health
2 shared publications Gabrielle Grubbs
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA
2 shared publicationsMing Zhao
Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
2 shared publicationsMotoshi Suzuki
Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
2 shared publications- Peter D. Sun
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health
2 shared publications Youri Lee
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20993, USA
2 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (11) , e0063325
Vaccination protects against COVID-associated pulmonary fibrin deposition
Understanding the protective mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines against severe COVID is important for therapeutic development to mitigate disease-associated lung pathologies. Here, we investigated the association between vaccination and the disease severity with a particular emphasis on viral-induced pulmonary fibrin formation in 43 COVID individuals. While COVID vaccination reduced the disease severity in this cohort, their plasma coagulation indices, including prothrombin time (PT), partial thromboplastin time (PTT), and D-dimer concentrations, remain unchanged between the vaccinated and non-vaccinated individuals. In contrast, vaccination lowered pulmonary inflammatory and coagulation signatures, reduced fibrinogen concentrations, and prevented prothrombin activation in bronchoalveolar lavage fluid (BALF), such that no viral-induced fibrin was observed in the vaccinated BALF. The formation of viral-induced fibrin correlated with the disease severity and was observed in non-vaccinated BALF samples containing high concentrations of fibrinogen and prothrombin, suggesting vaccination protected against the viral-induced pulmonary fibrin formation. Our finding highlights the use of pulmonary rather than plasma fibrinogen levels as a risk indicator for severe COVID disease. IMPORTANCE: Understanding the protective mechanism of COVID-19 vaccines against the severity of the disease is important for therapeutic development, and thus, subject to intense investigation. Here, we studied a cohort of 43 COVID patients based on their vaccination status. We showed that (i) COVID disease severity is associated with the formation of SARS-CoV-2-induced pulmonary fibrin, (ii) vaccination protected against severe COVID disease by reducing infiltration of coagulants, preventing prothrombin activation and fibrin deposition in infected lungs, and (iii) plasma coagulation indices are not useful indicators for fibrin deposition in infected lungs. Rather, the level of pulmonary fibrinogen provides an informative indicator for COVID-associated coagulation in lung.
- 25 November 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (11) , e0063325
Open AccessVaccination protects against COVID-associated pulmonary fibrin deposition
Understanding the protective mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines against severe COVID is important for therapeutic development to mitigate disease-associated lung pathologies. Here, we investigated the association between vaccination and the disease severity with a particular emphasis on viral-induced pulmonary fibrin formation in 43 COVID individuals. While COVID vaccination reduced the disease severity in this cohort, their plasma coagulation indices, including prothrombin time (PT), partial thromboplastin time (PTT), and D-dimer concentrations, remain unchanged between the vaccinated and non-vaccinated individuals. In contrast, vaccination lowered pulmonary inflammatory and coagulation signatures, reduced fibrinogen concentrations, and prevented prothrombin activation in bronchoalveolar lavage fluid (BALF), such that no viral-induced fibrin was observed in the vaccinated BALF. The formation of viral-induced fibrin correlated with the disease severity and was observed in non-vaccinated BALF samples containing high concentrations of fibrinogen and prothrombin, suggesting vaccination protected against the viral-induced pulmonary fibrin formation. Our finding highlights the use of pulmonary rather than plasma fibrinogen levels as a risk indicator for severe COVID disease. IMPORTANCE: Understanding the protective mechanism of COVID-19 vaccines against the severity of the disease is important for therapeutic development, and thus, subject to intense investigation. Here, we studied a cohort of 43 COVID patients based on their vaccination status. We showed that (i) COVID disease severity is associated with the formation of SARS-CoV-2-induced pulmonary fibrin, (ii) vaccination protected against severe COVID disease by reducing infiltration of coagulants, preventing prothrombin activation and fibrin deposition in infected lungs, and (iii) plasma coagulation indices are not useful indicators for fibrin deposition in infected lungs. Rather, the level of pulmonary fibrinogen provides an informative indicator for COVID-associated coagulation in lung.
- Open Access
- 11 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
SARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition
Severe COVID-associated lung injury is a major confounding factor of hospitalizations and death with no effective treatments. Here, we describe a non-classical fibrin clotting mechanism mediated by SARS-CoV-2 infected primary lung but not other susceptible epithelial cells. This infection-induced fibrin formation is observed in all variants of SARS-CoV-2 infections, and requires thrombin but is independent of tissue factor and other classical plasma coagulation factors. While prothrombin and fibrinogen levels are elevated in acute COVID BALF samples, fibrin clotting occurs only with the presence of viral infected but not uninfected lung epithelial cells. We suggest a viral-induced coagulation mechanism, in which prothrombin is activated by infection-induced transmembrane serine proteases, such as ST14 and TMPRSS11D, on NHBE cells. Our finding reveals the inefficiency of current plasma targeted anticoagulation therapy and suggests the need to develop a viral-induced ARDS animal model for treating respiratory airways with thrombin inhibitors.
- 11 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessSARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition
Severe COVID-associated lung injury is a major confounding factor of hospitalizations and death with no effective treatments. Here, we describe a non-classical fibrin clotting mechanism mediated by SARS-CoV-2 infected primary lung but not other susceptible epithelial cells. This infection-induced fibrin formation is observed in all variants of SARS-CoV-2 infections, and requires thrombin but is independent of tissue factor and other classical plasma coagulation factors. While prothrombin and fibrinogen levels are elevated in acute COVID BALF samples, fibrin clotting occurs only with the presence of viral infected but not uninfected lung epithelial cells. We suggest a viral-induced coagulation mechanism, in which prothrombin is activated by infection-induced transmembrane serine proteases, such as ST14 and TMPRSS11D, on NHBE cells. Our finding reveals the inefficiency of current plasma targeted anticoagulation therapy and suggests the need to develop a viral-induced ARDS animal model for treating respiratory airways with thrombin inhibitors.
- Open Access
- 15 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (42)
Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2–infected individuals reveal unlinked immune signatures
Mucosal SARS-CoV-2 immune profiles are divergent in asymptomatic versus symptomatic SARS-CoV-2–infected individuals.
- 15 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (42)
Open AccessSystemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2–infected individuals reveal unlinked immune signatures
Mucosal SARS-CoV-2 immune profiles are divergent in asymptomatic versus symptomatic SARS-CoV-2–infected individuals.